PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Thrombotic Microangiopathies

Drugs in development · updated 30 October 2026

Thrombotic Microangiopathies: drugs in development

As of 30 October 2026 there are 6 active clinical trials (recruiting or ongoing, phases I–III) on 6 drugs for thrombotic Microangiopathies. 3 are experimental, that is not yet approved in the United States.

6Active trials
3Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
IptcaopanIII1NCT05795140
KP104II1NCT05504187
TGD001I–II1NCT07459114

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
IptacopanLNP023, Fabhalta®III1NCT05935215
N-AcetylcysteineAcetylcysteine, AcetadoteII–III1NCT07279610
NarsoplimabYartemlea®II1NCT05855083

Sorted by most advanced phase and number of active trials.

All 6 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D057049 “Thrombotic Microangiopathies”.

ItalianoFrançaisDeutsch